Immunomodulation with CTLA4-Ig in islet transplantation

Transplantation

Volumn 73, Issue 1 SUPPL., 2002, Pages

  Benhamou, Pierre Y ^a  

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CALCINEURIN INHIBITOR; CD28 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; HYBRID PROTEIN; INTERLEUKIN 2 RECEPTOR ANTIBODY; RAPAMYCIN; STEROID;

ANTIGEN BINDING; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ANTIGEN RECOGNITION; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CONFERENCE PAPER; GENETIC ENGINEERING; GRAFT SURVIVAL; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; MEMORY CELL; NONHUMAN; PANCREAS ISLET TRANSPLANTATION; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

EID: 0037080929     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200201151-00013     Document Type: Conference Paper

References (33)

1. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen
2. ICOS co-stimulatory receptor is essential for T-cell activation and function
3. CTLA4 alanine-17 confers genetic susceptibility to Graves' disease and to type 1 diabetes mellitus
4. NOD Idd5 locus controls insulitis and diabetes and overlaps the orthologous CTLA4/IDDM12 and NRAMP1 loci in humans
5. Islet-infiltrating T lymphocytes in insulin-dependent diabetic patients express CD80 (B7-1) and CD86 (B7-2)
6. Appearance of cells expressing CD80 and CD86 costimulatory antigens in the pancreas of nonobese diabetic mice
7. Apoptosis resistance of nonobese diabetic peripheral lymphocytes linked to the Idd5 diabetes susceptibility region
8. Low CD86 expression in the nonobese diabetic mouse results in the impairment of both T cell activation and CTLA-4 up-regulation
9. CD28/B7 regulation of Th1 and Th2 subsets in the development of autoimmune diabetes
10. Autoimmunity without diabetes in transgenic mice expressing beta cell-specific CD86, but not CD80: Parameters that trigger progression to diabetes
11. Mice expressing both B7-1 and viral glycoprotein on pancreatic beta cells along with glycoprotein-specific transgenic T cells develop diabetes due to a breakdown of T-lymphocyte unresponsiveness
12. Expression of the co-stimulator molecule B7-1 in pancreatic beta-cells accelerates diabetes in the NOD mouse
13. Tissue immunogenicity: The role of MHC antigen and the lymphocyte costimulator B7-1
14. CD28/B7 costimulation regulates autoimmune diabetes induced with multiple low doses of streptozotocin
15. Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse
16. Immunomodulation of pancreatic islet allografts in mice with CTLA4Ig secreting muscle cells
17. Improved survival of biolistically transfected mouse islet allografts expressing CTLA4-Ig or soluble Fas ligand
18. Ex vivo coating of islet cell allografts with murine CTLA4/Fc promotes graft tolerance
19. Protective effect of CTLA4-Ig secreted by transgenic fetal pancreas allografts
20. A dendritic cell line genetically modified to express CTLA4-Ig as a means to prolong islet allograft survival
21. Prevention of autoimmune recurrence and rejection by adenovirus-mediated CTLA4-Ig gene transfer to the pancreatic graft in BB rat
22. CTLA4-Ig attenuates accelerated rejection (presensitization) in the mouse islet allograft model
23. Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4-Ig
24. CTLA4-Ig prolongs survival of microencapsulated neonatal porcine islet xenografts in diabetic NOD mice
25. Cyclophosphamide, but not CTLA4Ig, prolongs survival of fetal pig islet grafts in anti-T cell monoclonal antibody-treated NOD mice
26. Prolonged xenograft survival of islets infected with small doses of adenovirus expressing CTLA4-Ig
27. CTLA4 mediates antigen-specific apoptosis of human T cells
28. CTLA4 signals are required to optimally induce allograft tolerance with combined donor-specific transfusion and anti-CD154 monoclonal antibody treatment
29. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates
30. Immunosuppressive effects of human CTLA4-Ig in a non-human primate model of allogeneic pancreatic islet transplantation
31. + T cell apoptosis but not immune deviation
32. SICAM-1/Ig based gene therapy induces durable remission of established autoimmune diabetes through active tolerance
33. CTLA4-Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris